Cécile Bonnafous

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Holbrook E. Kohrt, Ariane Thielens, Aurélien Marabelle et al. · Blood · 2013 · 274 citations

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Don M. Benson, Courtney E. Bakan, Shuhong Zhang et al. · Blood · 2011 · 199 citations · Full text

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial

M. Bagot, Pierluigi Porcu, Anne Marie‐Cardine et al. · The Lancet Oncology · 2019 · 154 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Autoimmune Disease +8

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

Julie Gertner-Dardenne, Cécile Bonnafous, Christine Bezombes et al. · Blood · 2009 · 139 citations · Full text

Healthy Subjects, Immunotoxicology, Apoptosis +19

Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models

Florence Lhospice, Delphine Brégeon, Christian Belmant et al. · Molecular Pharmaceutics · 2015 · 107 citations